Other substances

Nb21

An anti-RBD (SARS-CoV-2 spike protein) nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Nb21 is a single-domain antibody (nanobody) identified in serum of a llama immunized by RBD of the SARS-CoV-2 spike protein. The nanobodody was selected based on its structure, RBD-binding and capacity to neutralize SARS-CoV-2 (pseudo)virus in vitro (Xiang et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Spike protein Biophysical assay In vitro Antibody 		in vitro biophysical assay; 293T-hsACE2 cells; Vero E6 cells; pseudotyped SARS-CoV-2 (Wuhan-Hu-1 strain); SARS-CoV-2 (Munich strain) 41.85

Manifests strong affinity to the SARS-CoV-2 spike protein RBD. Potently neutralizes the pseudotyped virus (IC50 0.045 nM) and live virus (IC50 0.022 nM). The nanobody is highly stable when stored.

 Nov/05/2020
Export (.csv)